Author:
Wysota Michael,Konopleva Marina,Mitchell Shane
Abstract
Abstract
Purpose of Review
This review seeks to identify and describe novel genetic and protein targets and their associated therapeutics currently being used or studied in the treatment of acute myeloid leukemia (AML).
Recent Findings
Over the course of the last 5–6 years, several targeted therapies have been approved by the FDA, for the treatment of both newly diagnosed as well as relapsed/refractory AML. These novel therapeutics, as well as several others currently under investigation, have demonstrated activity in AML and have improved outcomes for many patients.
Summary
Patient outcomes in AML have slowly improved over time, though for many patients, particularly elderly patients or those with relapsed/refractory disease, mortality remains very high. With the identification of several molecular/genetic drivers and protein targets and development of therapeutics which leverage those mechanisms to target leukemic cells, outcomes for patients with AML have improved and continue to improve significantly.
Publisher
Springer Science and Business Media LLC
Reference91 articles.
1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Cancer stat facts: leukemia, acute myeloid leukemia (AML). National Cancer Institute, DCCPS, Surveillance Research Program. 2023. https://seer.cancer.gov/statfacts/html/amyl.html
2. Rausch C, Rothenberg-Thurley M, Dufour A, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37(6):1234–44. https://doi.org/10.1038/s41375-023-01884-2.
3. Sasaki K, Ravandi F, Kadia TM, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049–61. https://doi.org/10.1002/cncr.33458.
4. Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41. https://doi.org/10.1038/s41408-021-00425-3.
5. DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–32. https://doi.org/10.1182/blood.2019001982.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献